KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash from Operations (2023 - 2025)

Biocryst Pharmaceuticals' Cash from Operations history spans 9 years, with the latest figure at 291960000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 5700.61% year-over-year to 291960000.0; the TTM value through Dec 2025 reached 347369000.0, up 767.76%, while the annual FY2025 figure was 347369000.0, 767.76% up from the prior year.
  • Cash from Operations reached 291960000.0 in Q4 2025 per BCRX's latest filing, up from 41624000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 291960000.0 in Q4 2025 to a low of 53684000.0 in Q1 2024.
  • Average Cash from Operations over 3 years is 16684000.0, with a median of 7065500.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: decreased 12.99% in 2024, then skyrocketed 5700.61% in 2025.
  • A 3-year view of Cash from Operations shows it stood at 8918000.0 in 2023, then soared by 41.55% to 5213000.0 in 2024, then surged by 5700.61% to 291960000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Cash from Operations are 291960000.0 (Q4 2025), 41624000.0 (Q3 2025), and 41302000.0 (Q2 2025).